JP2025143324A5 - - Google Patents

Info

Publication number
JP2025143324A5
JP2025143324A5 JP2025107051A JP2025107051A JP2025143324A5 JP 2025143324 A5 JP2025143324 A5 JP 2025143324A5 JP 2025107051 A JP2025107051 A JP 2025107051A JP 2025107051 A JP2025107051 A JP 2025107051A JP 2025143324 A5 JP2025143324 A5 JP 2025143324A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
terlipressin
patient
salt
continuous infusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025107051A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025143324A (ja
Filing date
Publication date
Priority claimed from JP2020115254A external-priority patent/JP2020172520A/ja
Application filed filed Critical
Publication of JP2025143324A publication Critical patent/JP2025143324A/ja
Publication of JP2025143324A5 publication Critical patent/JP2025143324A5/ja
Pending legal-status Critical Current

Links

JP2025107051A 2015-06-30 2025-06-25 腹水の治療 Pending JP2025143324A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201562186638P 2015-06-30 2015-06-30
US62/186,638 2015-06-30
US201562267510P 2015-12-15 2015-12-15
US62/267,510 2015-12-15
US201662321558P 2016-04-12 2016-04-12
US62/321,558 2016-04-12
JP2020115254A JP2020172520A (ja) 2015-06-30 2020-07-03 腹水の治療
JP2022107055A JP2022136104A (ja) 2015-06-30 2022-07-01 腹水の治療
JP2023133333A JP2023160839A (ja) 2015-06-30 2023-08-18 腹水の治療

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2023133333A Division JP2023160839A (ja) 2015-06-30 2023-08-18 腹水の治療

Publications (2)

Publication Number Publication Date
JP2025143324A JP2025143324A (ja) 2025-10-01
JP2025143324A5 true JP2025143324A5 (https=) 2025-10-15

Family

ID=57609113

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2016128584A Pending JP2017014206A (ja) 2015-06-30 2016-06-29 腹水の治療
JP2018145654A Pending JP2018172440A (ja) 2015-06-30 2018-08-02 腹水の治療
JP2020115254A Pending JP2020172520A (ja) 2015-06-30 2020-07-03 腹水の治療
JP2022107055A Pending JP2022136104A (ja) 2015-06-30 2022-07-01 腹水の治療
JP2023133333A Pending JP2023160839A (ja) 2015-06-30 2023-08-18 腹水の治療
JP2025107051A Pending JP2025143324A (ja) 2015-06-30 2025-06-25 腹水の治療

Family Applications Before (5)

Application Number Title Priority Date Filing Date
JP2016128584A Pending JP2017014206A (ja) 2015-06-30 2016-06-29 腹水の治療
JP2018145654A Pending JP2018172440A (ja) 2015-06-30 2018-08-02 腹水の治療
JP2020115254A Pending JP2020172520A (ja) 2015-06-30 2020-07-03 腹水の治療
JP2022107055A Pending JP2022136104A (ja) 2015-06-30 2022-07-01 腹水の治療
JP2023133333A Pending JP2023160839A (ja) 2015-06-30 2023-08-18 腹水の治療

Country Status (7)

Country Link
US (6) US9655945B2 (https=)
EP (2) EP3347032B1 (https=)
JP (6) JP2017014206A (https=)
CN (2) CN106999539A (https=)
ES (1) ES2971959T3 (https=)
HK (1) HK1258611A1 (https=)
WO (1) WO2017004317A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102176900B (zh) 2008-09-17 2017-09-26 克艾思马有限公司 药物组合物和相关的给药方法
HUE058066T2 (hu) 2014-10-24 2022-06-28 Mallinckrodt Pharmaceuticals Ireland Ltd Terlipressin 1-es típusú hepatorenális szindróma kezelésére
HUE071943T2 (hu) 2015-02-03 2025-10-28 Amryt Endo Inc Akromegália kezelése oktreotid orális alkalmazásával
JP2017014206A (ja) * 2015-06-30 2017-01-19 ナノアンティバイオティクス，インコーポレイテッド 腹水の治療
CA3037581A1 (en) 2016-10-21 2018-04-26 Chiasma, Inc. Terlipressin compositions and their methods of use
CN112704727B (zh) * 2021-01-12 2023-05-16 重庆医科大学附属第二医院 特利加压素在制备动力性肠梗阻药物中的应用
CN113077888A (zh) * 2021-03-30 2021-07-06 福州宜星大数据产业投资有限公司 自动化meld评分方法、终端及存储介质
JP2025505010A (ja) * 2022-02-03 2025-02-19 バイオビー インコーポレーテッド テルリプレシンを用いた疾患の治療方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1188443A1 (en) * 2000-09-15 2002-03-20 Ferring BV Improved protocol for paracentesis
HUE027174T2 (en) * 2006-02-13 2016-10-28 Ferring Bv Use of peptide agonists of the vasopressin receptor
WO2009037586A2 (en) * 2007-08-14 2009-03-26 Ferring B.V. Use of peptidic vasopressin receptor agonists
EP2203172A2 (en) * 2007-09-28 2010-07-07 Ferring B.V. Use of v2 receptor antagonists in combination with vasopressinergic agonists
EP2214709A4 (en) * 2007-11-08 2011-05-11 Univ Utah Res Found USE OF ANGIOGENESIS ANTAGONISTS IN DISEASES WITH ANOMAL VENEER PREPARATION
US8815232B2 (en) 2008-08-26 2014-08-26 Kyon Biotech Ag Compositions and methods for treating cancer
US9464284B2 (en) * 2009-03-09 2016-10-11 Bioatla, Llc Mirac proteins
EA201691430A1 (ru) * 2009-06-08 2017-02-28 ЮСиЭл БИЗНЕС ПиЭлСи Лечение портальной гипертензии и восстановление функции печени с помощью l-орнитинфенилацетата
WO2012009545A1 (en) * 2010-07-14 2012-01-19 Cumberland Emerging Technologies, Inc Methods of treating hepatorenal syndrome and hepatic encephalopathy with thromboxane-a2 receptor antagonists
WO2013106072A1 (en) * 2012-01-10 2013-07-18 Sorbent Therapeutics, Inc. Compositions comprising crosslinked cation-binding polymers and uses thereof
JO3109B1 (ar) 2012-05-10 2017-09-20 Ferring Bv منبهات لمستقبلات v1a
CN102731625B (zh) * 2012-06-27 2014-10-15 深圳翰宇药业股份有限公司 一种纯化特利加压素的方法
WO2014075082A1 (en) * 2012-11-12 2014-05-15 Gregory Thomas Everson Disease severity index for assessment of chronic liver disease and method for diagnosis of three distinct subtypes of primary sclerosing cholangitis
CN105592855A (zh) * 2013-04-26 2016-05-18 拉卓拉药物公司 用于治疗肾衰竭的组合物和方法
US20150056194A1 (en) 2013-08-21 2015-02-26 Georgia Regents Research Institute, Inc. Modified green tea polyphenols and methods thereof for treating liver disease
JP2017014206A (ja) * 2015-06-30 2017-01-19 ナノアンティバイオティクス，インコーポレイテッド 腹水の治療

Similar Documents

Publication Publication Date Title
JP2025143324A5 (https=)
JP2023002544A5 (https=)
US4405596A (en) Pharmaceutical preparations for and treatment procedures involving increasing plasma bicarbonate level
Soussi et al. Chloride toxicity in critically ill patients: What's the evidence?
CN106999539A (zh) 腹水的治疗
JP2023115271A5 (https=)
JP2018172440A5 (https=)
Nolph et al. Effects of intraperitoneal nitroprusside on peritoneal clearances in man with variations of dose, frequency of administration and dwell times
JP2021523125A5 (https=)
JP3168669B2 (ja) 肝再生促進剤
da Silva et al. Post-transplantation encapsulating peritoneal sclerosis in a pediatric patient
EP3220911B1 (en) Levosimendan for use as a liver protector
Misra et al. Peritoneal Dialysis in Diabetic End-Stage Kidney Disease
JP5034944B2 (ja) インターフェロン作用物質の活性増強剤
US11931376B1 (en) Methods for the treatment of chronic kidney disease
CN114796246B (zh) 一种用于治疗心力衰竭的药物及其用途
CN107308121A (zh) 肝脏再生的治疗剂
Kogelmann Use of CytoSorb in septic multiple organ failure following intestinal ischemia due to volvulus with concomitant liver failure after COVID-19 disease
CN117547537B (zh) Fn-1501及其药物组合物的应用
JPWO2019213558A5 (https=)
Gensy et al. Successful treatment of oral acetic acid poisoning with plasmapheresis
Delik et al. Treatment Approach in Patients with Decompensated Liver
Harvey Peritoneal dialysis solutions
Ha et al. Preservation of Residual Renal Function in Children Reaching End-Stage Renal Disease
EP3288562B1 (en) Method for improving kidney and/or heart function in patients with kidney disease